Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

META-BRAIN MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulation

Coordinator
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Spain
Runs
1 January 2024 to 30 April 2027
Status
Running
EU funding
€3.5m
Total cost
€3.5m
Partners
8 organisations in 5 countries
Type
European Innovation Council
Grant agreement
101130650

What the project is doing

In the project's own words, from its summary on CORDIS.

The pathological alterations of neurological function (e.g., stroke, trauma, neurodegeneration, epilepsy, neuropsychiatric diseases, chronic pain) are commonly associated with alterations in brain rhythms and activity patterns. There is an urgent clinical need for treatments that can precisely control and restore neural activity, taking advantage of state-of-the-art technological developments in a variety of fields including nanotechnology, nano- and microelectronics, novel materials, brain science, clinical neurology, and computational modelling.

META-BRAIN (MagnetoElectric and Ultrasonic Technology for Advanced BRAIN modulation) brings together seven expert partners in these fields with the aim of achieving precise spatiotemporal control of brain activity using magnetoelectric nanoarchitectures that can be polarized by non-invasive, remote magnetic fields. This novel principle of brain activity control will minimize the amplitude of the required magnetic fields, be wireless, and have enhanced spatial resolution from single neurons to cortical areas.

We will develop a model-driven fabrication of the coils and monitor the effects on brain function with arrays of graphene microtransistors that uniquely allow full-band recording, integrating all elements in a closed loop. As an alternative to remote brain stimulation we will also use novel ultrasonic technologies. The META-BRAIN control paradigm will be systematically studied in pre-clinical systems from individual neurons to the full brain.

All developments and experiments will be carried out in conjunction with theoretical models that will simulate, quantify, and predict optimal arrangements and patterns for the desired output. Translation to humans will be evaluated with our clinical partners, and a detailed dissemination and exploitation plan will be developed by two expert company partners, one of which has extensive expertise in the fabrication of brain interface devices with a worldwide distribution capability.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainCoordinator
G.tec Medical Engineering GmbHSchiedlbergAustriaParticipant
Eidgenoessische Technische Hochschule ZuerichZuerichSwitzerlandAssociatedpartner
Kypriako Idryma Erevnon Gia Ti Myiki DistrofiaAgios DometiosCyprusParticipant
Consorcio Centro De Investigacion Biomedica En Red M.p.MadridSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Zabala Innovation Consulting SAMutilva Alta NavarraSpainParticipant
Consiglio Nazionale Delle RicercheRomaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI